Acute Kidney Injury: Prevention, detection and follow-up in Primary Care April 2017.

Slides:



Advertisements
Similar presentations
Chronic kidney disease
Advertisements

Chronic kidney disease
Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
Prescribing in Chronic Renal Disease. Who has chronic renal disease (CKD)? CKD stages 1-V How common is it? Creatinine v GFR Basic Principles Scenarios.
FY1 Teaching Nov 30th 2011 Dr Jack Bond ST5 Nephrology
ACUTE KIDNEY INJURY Martin Havrda. Acute kidney injury - RIFLE Risk –50% rise of s-creatinine –25% drop of GFR –Urine output < 0,5 ml/kg.h during 6 hours.
The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Internal Medicine/Pediatrics.
CKD In Primary Care Dr Mohammed Javid.
National Institute for Health and Clinical Excellence.
The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,
+ Causes of Acute Kidney Injury Amy Livesey. + Overview Why Acute Kidney Injury? Definition Recap of types of AKI Causes of Acute Kidney Injury How to.
Adult Medical-Surgical Nursing Renal Module: Acute Renal Failure.
Managing hypertension in primary care
Pharmacological Treatment of Hypertension Update 2012.
Acute Kidney Injury Dr Andrew Lewington
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Section 6: Management in primary care Particular emphasis on nurse practitioner’s role.
LUTS Shawket Alkhayal Consultant Urological Surgeon Benenden Hospital Tunbridge Wells Nuffield Hospital.
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
Acute care toolkit 12 Acute kidney injury and intravenous fluid therapy.
Hypertension NICE CG127 August Hypertension is not a disease it is a risk factor for cardiovasuclar disease (CVD)-it is a modifiable risk factor.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Acute kidney injury Vivian Phan.
Acute Kidney Injury and the implications for community and practice nurses Claire Stocks – Sister, Cardiac Arrest Prevention Team, County Durham & Darlington.
Quality Education for a Healthier Scotland Pharmacy Pharmaceutical Care Planning Vocational Training Scheme: Level = Stage 2 Arlene Shaw Specialist Clinical.
An Introduction to Acute Kidney Injury (AKI)
+ Acute Kidney Injury Finals Teaching 2014 Alison Portes FY1.
MEERA LADWA ACUTE KIDNEY INJURY. WHAT IS ACUTE KIDNEY INJURY? A rapid fall in glomerular filtration rate (GFR) In practice, since measuring GFR is difficult,
Acute Kidney Injury (AKI) Based on NICE Guidelines Tariq Rehman Consultant Physician.
Acute Renal Failure. Approach to acute renal failure… Classifying the cause: –PreRenal (30%). –IntraRenal/Intrinsic cause (65%). –PostRenal (5%).
NICE Chronic Kidney Disease (CKD) Guidance 2014 Chronic kidney disease in adults: assessment and management (CG182)
Key facts about AKI 5 Facts about acute kidney injury (AKI), formerly known as "acute renal failure“ Up to 20% of hospital admissions have AKI Up to 25%
Medicines and CKD Nikki Lawton Medicines Optimisation Pharmacist NMCCG.
DRUGS AND THE KIDNEY DR.ALI A.ALLAWI ASSISTANT PROFESOR CONSULTANT NEPHROLOGIST.
Presentation by JoAnn Czech RN/CDS St. Cloud Hospital.
NHS Specialist Pharmacy Service NSAIDS – efficacy and safety Expert speaker Slide set Key content from the NPC NSAIDS QIPP slides is gratefully acknowledged.
Acute Kidney Injury. 100,000 deaths are year are associated with acute kidney injury. (NCEPOD 2009)
Acute Kidney Injury and the implications for community and practice nurses Claire Stocks – Sister, Cardiac Arrest Prevention Team, County Durham & Darlington.
Hypertension in primary care
Clair Huckerby Pharmaceutical Public Health Team Dudley CCG
Clinical Management of primary hypertension
An AKI project for critically ill cancer patients
Section 6: Management in primary care
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
Diuretics Thiazides are the preferred type of diuretic for treating hypertension, and all are equally effective in lowering blood pressure. In patients.
Based on work of the PPRNet
ACUTE KIDNEY INJURY Lecture by : Dr. Zaidan Jayed Zaidan
Presented By Dr / Said Said Elshama
Drugs for Hypertension
Developed by 91 Civil Affairs Presented/modified by 1BCT, 82D ABN DIV
Medication and Acute Kidney Injury
Acute Kidney Injury James Finnerty.
National Clinical Director (Renal)
Acute Kidney Injury (AKI)
Traditional parenteral antihypertensive treatment
MANAGING KIDNEY DISEASE IN PRIMARY CARE
Diuretics, Kidney Diseases Urine R&M
“the national perspective” Medical Director of the UK Renal Registry
The Urinary System Lesson 2: Pathology of the Urinary System
RCHC’s Cardiovascular Health Initiative
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Primary Hypertension Max C. Reif, M.D.
AKI – Acute Kidney Injury
New Advice for AKI Detection and Prevention in Primary Care
Pharmacological Treatment of Hypertension Update 2012
Hypertension Implementing NICE guidance 2 nd Edition March 2013 NICE clinical guideline 127.
Consultant Clinical Biochemist
Renal Pharmacy Beginners Guide - Lecture 5
Dr Donal O’Donoghue National Clinical Director for Kidney Care
Presentation transcript:

Acute Kidney Injury: Prevention, detection and follow-up in Primary Care April 2017

Introduction Why focus on AKI? Recognised as patient safety priority by NHS England Up to 100,000 deaths a year in hospital are associated with AKI ~1 in 5 people admitted to hospital as an emergency have AKI Estimated that up to 30% of cases preventable ~65% of AKI cases start in the community Ref: Think Kidneys National AKI Programme https://www.thinkkidneys.nhs.uk/aki/wp-content/uploads/sites/2/2017/02/NHS-Think-Kidneys-AKI-Programme-Review-and-Evaluation.pdf

Aetiology (1) 1. Prerenal AKI Many different underlying causes - three AKI categories:1 1. Prerenal AKI Most cases in community are prerenal - interruption to perfusion of kidneys Causes: - Hypovolaemia/volume depletion: haemorrhage, GI loss (diarrhoea, vomiting), sweating, burns, renal loss (diuretic overdose, osmotic diuresis [e.g. diabetic ketoacidosis]) - Intrarenal vasoconstriction (haemodynamically-mediated): effects of NSAIDs, ACEIs/ARBs, heart failure, liver failure, hypercalcemia Systemic vasodilation: sepsis, neurogenic shock 1. Rahman et al. Am Fam Physician. 2012:86:631-9

Aetiology (2) 2. Renal/intrinsic AKI Direct effects on different sites in kidney: Glomerular: glomerulonephritis Interstitial: drugs with nephrotoxic potential (penicillin analogues, cephalosporins, sulphonamides, ciprofloxacin, acyclovir, rifampin, phenytoin, PPIs, NSAIDs); infections, viruses Vascular: renal vein thrombosis; renal atheroembolic disease; renal infarction Tubular: prolonged hypotension; nephrotoxicity: exogenous nephrotoxic agents - radiographic contrast agents, aminoglycosides, methotrexate endogenous nephrotoxins: rhabdomyolysis, hemolysis, tumor lysis syndrome, myeloma )

5-10% AKI cases due to obstruction of urine flow Aetiology (3) 3. Post-renal AKI: 5-10% AKI cases due to obstruction of urine flow Causes: - renal stones - crystals (poorly soluble drugs) - tumours - enlarged prostate - bladder, prostate or cervical carcinoma

Most Common Causes of AKI Medication Vomiting/diarrhoea Diuretic overuse Sepsis Kidney stones Prolonged hypotension Radiographic contrast agents Diabetic Ketoacidosis A combination (e.g medication exacerbated by vomiting/diarrhoea)

Assessments if AKI present Assessment of volume status – temp; peripheral perfusion; heart rate/BP; jugular venous pressure; moistness of mucous membrane; skin turgor Renal function and serum potassium levels. To help identify possible causes, ask questions about: current symptoms: unwell? (diarrhoea, vomiting, breathlessness) recent symptoms for obstructive cause? (lower urinary tract symptoms, bloating from a pelvic mass, renal colic) drug history (including OTC, recreational drugs and herbal remedies) social history (tropical diseases [e.g. malaria], exposure to rodents [e.g. leptospirosis, hantavirus] Assess for renal disease by performing urine dipstick testing. Protein 3+/4+ suggest intrinsic glomerular disease; haematuria in presence of proteinuria suggests glomerular cause Haematuria may suggest lower urinary tract disease in association with tumours, calculi, infection, or severe renal ischaemia due to arterial or venous thrombosis. Increased white cells non-specific but may suggest infection (most common) or acute interstitial nephritis. Nitrites plus white cells may be due to pyelonephritis. Be aware that dipstick analysis of urine from people with catheters should be interpreted with caution because of the possibility of false positive results.

Role of primary care in AKI… Recognition of ‘at risk’ patients’ to help implement prevention strategies, improve chances of early detection Prompt delivery of interventions to help limit severity of AKI e.g. prompt response to new Early Warning Alerts (see later slide) timely provision of medicines ‘sick day’ guidance; provision of supportive advice, e.g. maintaining hydration awareness of criteria for referral/admission Delivery of post-AKI follow-up ongoing monitoring of renal function medication reviews limiting risk of further episodes, e.g. self-care advice to patients/carers

Recognising at-risk patients – risk factors (adults) - presence in patients presenting with acute illness should prompt suspicion and creatinine serum testing CKD (particularly if eGFR <60) Previous AKI Chronic conditions (heart failure, liver disease, diabetes) Sepsis Hypovolaemia (diarrhoea, vomiting) 65 years or over Use of nephrotoxic drugs in past week, especially if hypovolaemic (NSAIDs, ACEIs, ARBs, diuretics, aminoglycosides) Use of iodinated contrast agents within past week Low urine output (< 0.5 ml/kg/hour) Limited access to fluids (neurological/cognitive impairment; disability) Symptoms/history of urological obstruction

Responding to AKI Warning Alerts in Primary Care Automated delivery of AKI Warning Stage Alerts from pathology labs to practices based on creatinine test results GP can expect 1 alert every 1-2 months; mostly Stage 1s ‘Positive’ warning indicates ‘possibility’ of AKI; consideration of clinical context is key Possibility of false positives - e.g. normal increase in creatinine following pregnancy; anticipated drug-related increases) And false negatives – e.g. occurrence of AKI in the past year could result in spuriously high calculation of patient’s baseline creatinine

Responding to warning alerts ‘Think Kidney’s has published guidance on responding to these alerts – also includes staging and referral criteria See Think Kidney’s resource (www.thinkkidneys.nhs.uk/aki/wp-content/uploads/sites/2/2016/10/RespondingtoAKI-Warning-Stage-Test-Results-for-Adults-in-Primary-Care.pdf)

Medicines in AKI If AKI detected, “Think Medicines” MO guidance and suggested actions to take for a wide problematic medicines available from Think Kidneys… See Think Kidney’s website https://www.thinkkidneys.nhs.uk/aki/wp-content/uploads/sites/2/2016/03/Guidelines-for-Medicines-optimisation-in-patients-with-AKI-final.pdf

Other AKI resources …. ‘Think Kidneys’ website (www.thinkkidneys.nhs.uk) has lots more resources for….. Primary care: www.thinkkidneys.nhs.uk/aki/resources/primary-care/ Care homes: https://www.thinkkidneys.nhs.uk/aki/resources/care-homes Patients: range of leaflets available at https://www.thinkkidneys.nhs.uk/aki/resources/primary-care/

Workshop Questions AKI is usually caused by an acute insult on top of background morbidity. What are the top 5 background morbidity risk factors and top 3 acute insults. If a patient presents with these risk factors and AKI is suspected what do you do? Identify High Risk medicines in Patients where AKI is suspected For each medicine what action would you take If the patient is admitted to hospital with AKI what actions should be taken when the patient is discharged If any high risk medicines were stopped what action should be taken post AKI What key pieces of information would you put in a patient information leaflet about AKI

From London AKI Network Algorithm

Selected high-risk medicines - suggested actions to take in presence of AKI1 NSAIDs/COX II inhibitors: Avoid use Aminoglycosides: Avoid use if possible. If unavoidable, reduce dose &/or increase dosing interval. Monitor drug levels and renal function 2-3 times/week Trimethoprim: Avoid or reduce dose (particularly if patient is already taking an ACEi, ARB or spironolactone – and particularly elderly patients) Tetracycline: Avoid use Metformin: Avoid if GFR <30 ml/min Methotrexate: Avoid esp. if patient at risk of hyperkalaemia 5-aminosalicylates: Avoid use Tolvaptan ( Vasopressin V2 receptor antagonist): Stop and seek specialist advice.

Suggested action to take with antihypertensives Antihypertensives: Consider withholding/reduce dose depending on clinical signs. Some patients who continue taking beta-blockers during an episode of AKI have developed complete heart block and required temporary pacing. Thiazide & loop diuretics: Monitor and adjust dose as necessary. Potassium sparing diuretics: Avoid use. RAS drugs (ACEi/ARBs/aliskiren): Consider withholding. In some situations, e.g. heart failure with a decent blood pressure, continuing them might actually be helpful. If patient is hypertensive, consider alternative antihypertensive agents, e.g., calcium channel blockers, thiazide-type diuretics, alpha-blockers, beta-blockers if appropriate.

Post-AKI follow-up in primary care Been suggested that improvements required in primary care follow-up of patients after hospital stay complicated by AKI  Follow up: early review to assess renal recovery and review of medications that have may been stopped longer-term monitoring to development/progression of CKD: many people may have residual CKD NICE recommend monitoring renal function for 3 years post-AKI (CG169) opportunity to provide advice to patients/carers to limit further AKI episodes - e.g. advice on medicines to stop on ‘sick days’; importance of hydration

Post-AKI follow-up in primary care Example: Recent CCG initiative1 included development of post- discharge GP practice action plans. Key processes for plan: Coding: Has there been appropriate coding of AKI? Audit of this CCG found 75% of patients with AKI on discharge sheet did not have coding in primary care record. Medication Review: Has the patient had a medication review within 4 weeks post-discharge? Monitoring: Has kidney function been checked within 3 months? Communication: Has AKI risk been communicated to the patient (and carer)? 1.https://www.thinkkidneys.nhs.uk/aki/wp-content/uploads/sites/2/2017/02/Bury-AKI-Think-Kidneys-Case-Study.pdf

Restarting drugs after an AKI episode ACEIs, ARBs, diuretics commonly stopped during AKI. Think Kidneys resource on restarting1 – selected points: Review original indication for use of the drug - if specific contraindication, use alternative Heart failure patients: re-start ACEI/ARBs as soon as clinically reasonable re-titration (by either GP or heart failure service, if patients under service) CKD with albuminuria: restart ACEI/ARBs unless new contra-indication (e.g. serum potassium >5 mmol/L) 1. https://www.thinkkidneys.nhs.uk/aki/wp-content/uploads/sites/2/2016/02/When-to-restart-drugs-stopped-during-AKI-final.pdf

Restarting drugs after an AKI episode Patients with Hypertension:1 Review antihypertensive strategy and re-check BP - ideally ambulatory Bring prescribing into line with NICE CG127, if not already CCB 1st-line for >55’s and black people of African/AfroCaribbean origin For other patients, re-start drug unless potassium > 5 mmol/l, or risk of recurrent hypovolaemia, in which case consider alternatives Re-measure creatinine and potassium 1-2 weeks after starting and after any dose titration If patient left off treatment (e.g. clinic BP <140/90; home BP <130/85), further follow up should be offered for at least 12 months, as BP may take time to return to previous levels 1. https://www.thinkkidneys.nhs.uk/aki/wp-content/uploads/sites/2/2016/02/When-to-restart-drugs-stopped-during-AKI-final.pdf

Other AKI resources …. ‘Think Kidneys’ website (www.thinkkidneys.nhs.uk) has lots more resources for….. Primary care: www.thinkkidneys.nhs.uk/aki/resources/primary-care/ Care homes: https://www.thinkkidneys.nhs.uk/aki/resources/care-homes Patients: range of leaflets available at https://www.thinkkidneys.nhs.uk/aki/resources/primary-care/